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Abstract
We present revised Polish guidelines regarding the management of patients harbouring neuroendocrine neoplasms (NENs) of the small 
intestine and appendix. The small intestine, especially the ileum, is the most common origin of these neoplasms. Most of them are well dif-
ferentiated with slow growth. Rarely, they are less differentiated, growing fast with a poor prognosis. Since symptoms can be atypical, the 
diagnosis is often accidental. Typical symptoms of carcinoid syndrome occur in less than 10% of patients. The most useful laboratory marker 
is chromogranin A; 5-hydroxyindoleacetic acid is helpful in the monitoring of carcinoid syndrome. Ultrasound, computed tomography, 
magnetic resonance imaging, colonoscopy, video capsule endoscopy, balloon enteroscopy and somatostatin receptors scintigraphy are used 
in the visualisation. A histological report is crucial for the proper diagnostics and therapy of NENs, and it has been extensively described. 
The treatment of choice is surgery, either radical or palliative. Somatostatin analogues are crucial in the pharmacological treatment of 
the hormonally active and non-active small intestine NENs and NENs of the appendix. Radioisotope therapy is possible in patients with 
a good expression of somatostatin receptors. Chemotherapy is not effective in general. Everolimus therapy can be applied in patients with 
generalised NENs of the small intestine in progression and where there has been a failure or an inability to use other treatment options. 
Finally, we make recommendations regarding the monitoring of patients with NENs of the small intestine and appendix. 
(Endokrynol Pol 2013; 64 (6): 480–493)
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Streszczenie
W pracy przedstawiono uaktualnione polskie zalecenia postępowania z chorymi na nowotwory neuroendokrynne (NEN) jelita cienkiego 
i wyrostka robaczkowego. Jelito cienkie, a przede wszystkim jelito kręte jest miejscem najczęstszego występowania tych nowotworów. 
Większość z nich to nowotwory wysokozróżnicowane i wolno rosnące. Rzadko są to nowotwory niskozróżnicowane, szybko rosnące o 
niekorzystnym rokowaniu. Ich objawy mogą być nietypowe, a rozpoznanie przypadkowe. Typowe objawy zespołu rakowiaka występują 
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w mniej niż 10% przypadków. W diagnostyce laboratoryjnej najbardziej przydatne jest oznaczenie stężenia chromograniny A, badanie 
stężenia kwasu 5-hydroksyindolooctowego jest pomocne w monitorowaniu zespołu rakowiaka. W obrazowaniu stosuje się ultrasono-
grafię, tomografię komputerową, rezonans magnetyczny, kolonoskopię, wideoendoskopię kapsułkową, enteroskopię dwubalonową, 
scyntygrafię receptorów somatostatynowych. Szczegółowe badanie histologiczne jest kluczowym dla właściwego rozpoznania i leczenia 
chorych z NEN jelita cienkiego i wyrostka robaczkowego. Leczeniem z wyboru jest postępowanie chirurgiczne, radykalne lub paliatywne. 
W leczeniu farmakologicznym czynnych i nieczynnych hormonalnie NEN jelita cienkiego i wyrostka robaczkowego podstawowe zna-
czenie mają analogi somatostatyny. Terapia radioizotopowa u chorych z dobrą ekspresją receptorów somatostatynowych stanowi kolejną 
opcję terapeutyczną. Chemioterapia jest na ogół nieskuteczna. U pacjentów z rozsianym NEN jelita cienkiego i progresją choroby oraz 
nieskutecznością innych metod terapii można zastosować ewerolimus. Przedstawiono także zalecenia odnośnie monitorowania chorych 
z NEN jelita cienkiego i wyrostka robaczkowego. (Endokrynol Pol 2013; 64 (6): 444–493)
Słowa kluczowe: nowotwory neuroendokrynne; jelito cienkie; wyrostek robaczkowy; rakowiak; diagnostyka; terapia; zalecenia
Introduction 
Neuroendocrine neoplasms (NENs) of the small in-
testine originate in the midgut; the small intestine is 
the second (after the pancreas) most common place 
of their occurrence. From the clinical point of view, 
we distinguish between hormonally non-active 
NENs, and active ones that secrete substances which 
cause characteristic symptoms known as carcinoid 
syndrome. Most small intestinal NENs are well differ-
entiated and grow slowly. On rare occasions, they are 
poorly differentiated, with rapid growth and a poor 
prognosis. Tumours in this location are very rarely part 
of MEN syndromes [1–3].
NENs of the terminal part of the small intes-
tine and the appendix are mostly composed of EC 
(enterochromaffin) cells, responsible for serotonin 
production. Certain NENs have the ability to secrete 
enteroglucagon, glucagon and other peptides. It 
is believed that ileum NENs of that type are more 
aggressive than neuroendocrine neoplasms of the 
duodenum, tumours of the stomach built of ECL 
(enterochromaffin-like) cells, or of the rectum. They 
reveal higher metastatic ability, associated to a lesser 
degree with the size of the tumour [1–3].
1. Epidemiology
The small intestine, and particularly the ileum, are the most 
common NENs sites in the human body. Small intestinal 
NENs occur equally often in male and female patients; 
they affect all age groups, with the peak in the 6th and 7th 
decades of life. The estimated prevalence is 0.32–1.12 per 
100,000 of the population per year, including malignancy 
in 0.29 per 100,000; apart from the small intestine, they also 
affect the appendix and the midgut [4–10]. Post-mortem 
examinations have reported a possible prevalence of as 
much as 1.22% [11]. Tumours originating from the lower 
part of the jejunum and the ileum constitute 23–38% of 
all gastrointestinal endocrine neoplasms, and they are 
more common than endocrine neoplasms of the appen-
dix. Hormonally active neuroendocrine neoplasms of the 
small intestine are often multifocal, and in 15% of cases are 
associated with other neoplasms such as gastrointestinal 
adenocarcinoma or breast cancer [3].
The term ‘carcinoid’ is still associated with a certain 
ambiguity. In the past, the term referred to a  neu-
roendocrine neoplasm, regardless of the location of 
the primary tumour site or the level of malignancy. 
Later, in Europe, carcinoids were limited to neoplasms 
originating from the midgut, secreting serotonin and 
associated with carcinoid syndrome symptoms. How-
ever, the WHO 2010 classification of the gastrointestinal 
neuroendocrine neoplasms attributed the term carcinoid 
to G1 neuroendocrine neoplasms. The Polish Network 
of Neuroendocrine Tumours argues that the term ‘car-
cinoid’ should be relinquished, and substituted with 
the name ‘neuroendocrine tumour’ or ‘neuroendocrine 
neoplasm’ [2–4, 12, 13].
Over the last 30 years, the incidence of neuroen-
docrine neoplasms of the gastrointestinal tract has 
increased by 720%, and of the small intestine by 460%. 
In this period, within the small intestine there has also 
been an increase in the ileum neuroendocrine neo-
plasms rate, from 52% to 63.6%. This is very important, 
as neoplasms in this area in 58% of cases are malignant; 
this group of tumours constitutes no more than 35% of 
cases within the whole small intestine. A higher preva-
lence has been observed in African-Americans and in 
females compared to Caucasians and males. Although 
the increase in the incidence of gastric and rectal NENs 
can be partially explained by the development of endo-
scopic techniques, such an explanation does not apply 
to the higher prevalence of small intestinal NENs [2–4].
Most tumours are located in the terminal part of 
the ileum, in proximity to the ileocaecal valve. The 
prognosis is these cases is usually poor, as they often 
involve metastases to the regional lymph nodes, and 
then to the liver. It depends on the TNM staging assess-
ment and Ki67 grading [13]. The five-year survival rate 
is 100% for patients with stages I and II small intestinal 
NENs, 97.1% for patients with stage III, and 84.8% for 
patients with stage IV. Considering the level of tumour 
differentiation, the five-year survival rate was 93.8% for 
G1, 83% for G2, and 50% for G3 [14]. Other studies have 
reported the five-year survival rate to be 72% in patients 
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with local tumours, and 55% in patients with distant 
metastases [15]. Alternative European data shows the 
five-year survival rate to be 59–74% in patients with 
NENs of the small intestine and the appendix [8, 16]. 
Earlier observations revealed a ten-year survival rate of 
60% in patients without liver metastases at the diagno-
sis, and 15–25% in metastatic patients. The prognosis 
improves if the primary tumour is removed [3].
2. Clinical characteristics
2.1. Symptoms of the hormonally active NENs of 
the small intestine — carcinoid syndrome
Carcinoid syndrome occurs in approximately 4–10% of 
NENs patients, mainly with dispersed tumours located 
in the ileocaecal area. Carcinoid syndrome comprises 
symptoms resulting from an excessive secretion of 
serotonin and other biologically active compounds 
(including kinins, prostaglandins and histamine) by 
NENs. Serotonin secreted to the portal venous system is 
metabolised in the liver, and does not cause any clinical 
symptoms. The symptoms occur if serotonin and other 
biogenic amines are secreted directly to the systemic 
circulation; therefore, carcinoid syndrome symptoms 
occur most often with hepatic metastases from NENs 
(approximately 95% of cases) [1–4, 17].
Clinical symptoms of carcinoid syndrome include: 
(i) symptoms affecting the skin (flushing, telangiectasis, 
pellagra — skin inflammation caused by vitamin PP 
deficiency, resulting from the use of tryptophan for 
excessive serotonin production by the neoplasm); (ii) 
symptoms affecting the gastrointestinal tract (secretory 
diarrhoea, non-specific or colic abdominal pains); (iii) 
symptoms affecting the cardiovascular system (tricus-
pid valve disorders, diseases of the pulmonary trunk, 
rarely mitral valve and aorta disorders); (iv) symptoms 
affecting the musculoskeletal system (osteoarticular 
pains, myopathies) [18, 19].
Flushing is one of the main symptoms of carcinoid 
syndrome. Flushing that accompanies serotonin secret-
ing NENs of the small intestine (classical carcinoid syn-
drome) is pale-pink to red, affecting the face and upper 
chest, and lasting up to 30 minutes. Triggering factors 
include alcohol, spicy foods, emotional stress, and 
medications (serotonin reuptake inhibitors). Flushing 
in the case of foregut NENs (atypical form of carcinoid 
syndrome) is more intensive, with a crimson shade; it 
lasts longer (as much as a few days), affects the torso 
and upper limbs, and is often accompanied by lowered 
blood pressure and lacrimation [18].
The main causes of death in patients with carcinoid 
syndrome are heart diseases — referred to as carcinoid 
heart disease (CHD), which may affect 50% of patients. 
CHD is mainly characterised by plaques of fibrous tis-
sue on the valves of the right heart, leading to tricuspid 
valve regurgitation (the most common defect) and/or 
stenosis/regurgitation of the pulmonary valve. The left 
side of the heart is affected by the disease in less than 
10% of cases, and is associated with the presence of 
pulmonary NENs, or a right-to-left leak, for instance in 
the patent foramen ovale. At first, the clinical symptoms 
of CHD are weakly pronounced; then, the symptoms 
of right ventricular heart failure progress: weakness, 
exertional dyspnoea, oedemas and ascites develop. 
The prognosis for patients with CHD and severe heart 
failure (NYHA classes III and IV) is unfavourable; the 
mean survival rate for patients without cardiosurgical 
treatment is 11 months. The gold standard in CHD diag-
nosis is echocardiography, which should be performed 
in all patients with carcinoid syndrome [19–24].
Carcinoid crisis is a rare, life-threatening complica-
tion caused by a sudden release of biologically active 
substances to the systemic circulation. The symptoms 
include: prolonged skin redness, intense diarrhoea 
or vomiting, wheezing, blood pressure fluctuations, 
arrhythmia, disturbed nervous system function, dehy-
dration, shock, acute renal failure or hypercalcaemia. 
The crisis may occur independently, during infection, 
or as a result of medical procedures: general anaesthe-
sia, endoscopy, tumour biopsy, surgery, embolisation, 
radioisotope therapy or chemotherapy. Therefore, 
it is recommended to use somatostatin analogues in 
the pre-operative period or during surgery on NENs 
patients [25–27].
2.2. Symptoms of the hormonally non-active 
NENs of the small intestine
The clinical picture of the hormonally non-active 
NENs of the small intestine is related to local symp-
toms. Small tumours are usually asymptomatic; they 
are found while identifying the source of metastases, 
or accidentally during colonoscopy. Larger tumours, of 
more than 1 cm, are usually malignant and metastatic. 
Leading local symptoms include transient abdominal 
pains and discomfort lasting for years, and are often 
misinterpreted as functional disorders. Over time, 
the symptoms worsen and may result in transient 
obstructions of the small intestine caused by the 
presence of the tumour mass, or by the desmoplastic 
reaction of the mesentery. Moreover, the desmoplastic 
reaction can impair the blood supply in the intestines, 
resulting in intestinal ischaemia, and in severe cases 
leading to necrosis. A desmoplastic reaction rarely 
results in retroperitoneal fibrosis or hydronephrosis. 
Other non-specific symptoms include weight loss, 
weakness and rarely a fever of unknown aetiology. 
Severe gastrointestinal bleeding is a rare symptom of 
the small intestine NENs. In many cases of hormonally 
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non-active small intestinal NENs, the clinical picture is 
poorly expressed and highly non-specific; the patient 
is diagnosed due to discovered (often accidentally) 
hepatic metastases [2-4].
2.3. Symptoms of NENs of the appendix
Appendicitis is usually the first manifestation of carci-
noid in this location. Over 50% of neuroendocrine neo-
plasms of the appendix are discovered accidentally after 
appendectomy. Recent data indicates that metastases 
to the regional lymph nodes occur in 27% of cases, and 
distant metastases in 8.5% of cases [2–4].
Symptomatology of gastrointestinal neuroendo-
crine neoplasms, in particular tumours of the small 
intestine, favours diagnosis of these tumours in more 
advanced stages. While gastrointestinal neuroendo-
crine neoplasms are found in 45.4% as local lesions, in 
the case of the small intestine the rate is 31.3%. These 
values are much lower than those for NENs of the 
stomach, appendix and rectum, which have a better 
prognosis [2–4].
Most NENs of the appendix are diagnosed in 
earlier stages. This contributes to a high survival rate 
in patients with tumours in this location, which is 
particularly visible in children, where over 80% of the 
diagnosed tumours are smaller than 1 cm. The size of 
the tumour is of crucial importance for the occurrence 
of metastases: for tumours smaller than 1 cm in diam-
eter, metastases occur in 2%; for tumours of 1–2 cm in 
diameter, the figure is 50%; and for tumours bigger than 
2 cm, the figure is 80–90% of patients [2–4].
3. Diagnostics
3.1. Biochemical diagnostics
In the biochemical diagnostics of neuroendocrine 
neoplasms of the small intestine, it is useful to de-
termine the concentration of chromogranin A (CgA) 
— a sensitive, but not very specific, marker [2–4, 17, 28]. 
Determination and interpretation of the results have been 
described in the chapter on general GEP NENs diag-
nostics. A significantly increased CgA concentration 
(over 1,000 ng/mL) may be treated as an indicator of 
poor prognosis.
The assessment of 5-hydroxyindoleacetic acid 
(5-HIAA) excretion in urine is a sensitive tumour indi-
cator, useful for diagnosis and monitoring of disease 
progression or treatment in patients with carcinoid 
syndrome. The sensitivity and specificity of 5-HIAA 
determination in order to confirm carcinoid syndrome 
are 70% and 90%, respectively (for details, see the chap-
ter on general GEP NENs diagnostics) [2–4, 29]. The 
determination of blood serotonin levels can be helpful 
when 5-HIAA determination is ambiguous.
In diagnostics and assessment of the severity of 
carcinoid heart disease, the determination of 5-HIAA 
and NT-proBNP (N-terminal-pro-B-type natriuretic 
peptide) may be useful [2–4, 17, 30, 31].
Minimal consensus statement on biochemical tests:
 — CgA and 5-HIAA — in patients with suspected carcinoid 
syndrome (*evidence level 3);
 — CgA and 5-HIAA in all patients diagnosed with NEN of 
the small intestine before treatment, and during monitor-
ing (*evidence level 3);
 — NT-proBNP — in the case of carcinoid heart disease, in 
order to assess the severity (*evidence level 4).
3.2. Imaging diagnostics
The aim of diagnostic imaging of NENs in the small 
intestine is:
 — to present the primary focus;
 — to determine the local tumour size and presence of 
metastases;
 — to evaluate the response to treatment [32–34].
Computed tomography (CT) scanning is crucial 
for the location diagnostics of GEP NENs because it 
is a simple, easily available, and objective imaging 
method which allows locating the tumour precisely and 
enables a simultaneous assessment of potential tumour 
expansion i.e. invasion to the adjacent structures and 
metastases to the liver or lymph nodes. Preliminary 
diagnostics of small intestine diseases should involve 
CT enterography or MR enterography; for the follow-
up of small intestine diseases, MR enterography should 
be applied. MR enteroclysis should be performed in 
patients with a clinically suspected pathology of the 
small intestine and with negative MR/CT enterography 
results [35–37].
Multiphase — mostly three-phase — CT or magnetic 
resonance (MR) examinations after intravenous admini-
stration of the contrast agent are methods evaluating 
the stage of advancement of the neoplastic disease; 
they enable monitoring of the disease and assessment 
of the response to therapy, according to the RECIST 
criteria [38, 39].
Some NENs are visible only in the arterial phase 
of the study, that is for a maximum of approximately. 
30 seconds after the administration of contrast medi-
um. Therefore the CT and/or MR examination should 
be multiphase, with delays of 15 s, 30 s, and 80 s, and 
a layer thickness of 1–2.5 mm. The contrast material 
* evidence level according to CEBM [77]
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is administered intravenously, approximately 1.5 mL/ 
/kg b.w. In the case of MR imaging, the scans include: 
T1-weighted, T2-weighted, fat-saturated T2-weighted, 
DWI images with ADC maps, and dynamic imaging 
following the administration of a contrast agent. Both 
CT and MR examinations are characterised by a high 
sensitivity in diagnosing metastatic foci in the liver 
(88–90%). MR imaging is considered to be a second-
line examination in the assessment of hepatic metas-
tases; it is particularly important for the assessment of 
foci with a non-specific enhancement in the CT scan, 
and foci smaller than 10 mm. It is also recommended 
in patients allergic to iodine contrast agents used in 
CT imaging. CT and MR are also widely used in the 
diagnostics of metastases to organs other than the 
liver: lymph nodes, lungs and bones. In the compre-
hensive assessment of the severity of the neoplastic 
process, MR of the whole body can be used, including 
not only the standard T1-weighted, T2-weighted and 
fat-saturated T2-weighted images, but also DWI scans 
with ADC maps. Ultrasonography (USG) is of limited 
use in detecting the primary tumour site. Its sensitivity 
in the diagnosis of hepatic metastatic foci is estimated 
to be as much as 80%; however, it is a subjective test, 
and thus it is not recommended for the evaluation 
of response to treatment. Using anatomical methods 
together with functional ones is a standard procedure 
in diagnostics and assessment of response to the treat-
ment of NENs, because of the insufficient sensitivity 
and specificity of each examination alone, and due 
to the evaluation of the expression of somatostatin 
receptors [40–42]. 
3.2.1. Endoscopic diagnostics
Endoscopic diagnostics of the small intestine is usually 
undertaken to identify the primary tumour site in the 
case of metastases of an unknown origin (often signifi-
cantly larger than the primary tumour), in the case of 
non-specific abdominal symptoms, or to find the cause 
of gastrointestinal bleeding [43].
Classical endoscopy is of little importance in the 
diagnostics of small intestinal NENs. Although the 
direct presentation of a NEN located in the small 
intestine is possible during colonoscopy, when the 
tumour protrudes through the ileocaecal valve into 
the caecum lumen, such cases are very rare. Colonos-
copy is, however, important to exclude a concomitant 
neoplastic disease (primarily colorectal cancer). Endo-
scopic ultrasonography, unlike other locations of GEP 
NENs lesions, is of no use in the diagnostics of small 
intestine tumours [35–37].
Video capsule endoscopy (VCE) and balloon or 
spiral enteroscopy can be used for direct assessment of 
the jejunum and ileum mucosa, but these methods are 
not very available [35–37]. A full assessment of the small 
intestine is achieved in approximately 80% of patients, 
and the overall diagnostic efficiency of the test is ca. 55% 
[44]. VCE sensitivity in the diagnosis of neuroendocrine 
tumours is relatively low, and compared to CT entero-
graphy it is 29–37.5% v. 50–92%. Another disadvantage 
of VCE is inability to locate the tumour precisely [45–47]. 
Balloon enteroscopy or spiral enteroscopy are free of 
this shortcoming, but their diagnostic efficiency is not 
very high [48, 49]. 
It is worth emphasising that neuroendocrine neo-
plasms of the small intestine, due to secreted growth 
factors resulting in desmoplastic reactions of the mesen-
tery, often cause significant narrowing of the intestine, 
which is an absolute contraindication for video capsule 
endoscopy, because of the risk of capsule incarceration 
[50, 51].
3.3. Isotope diagnostics
Compared to radiological examinations, somatostatin 
receptor scintigraphy (SRS) with the use of radioiso-
tope-labelled SSA is a more sensitive method, especially 
while identifying the primary tumour site [52]. Indica-
tions for SRS include:
 — location of the primary site of the tumour;
 — determination of the stage of disease advancement;
 — monitoring of the patient following a radical surgical 
treatment (all patients with tumours located in the 
small intestine and tumours > 1 cm in the appendix);
 — qualification of patients for pharmacological treat-
ment and for isotope therapy with SSA.
The sensitivity of the study is over 80% for iden-
tification of the primary tumour site [53], whereas in 
the diagnostics of distant metastases it is over 90% 
[54]. PET/CT examination with Ga-68 labelled SSA 
[55] is the preferred approach, particularly when 
detecting small lesions of less than 1 cm [56].
Minimal consensus statement on imaging:
 — Abdominal ultrasound, three-phase multi-slice CT and/ 
/or MR and SRS with a labelled somatostatin analogue 
(SPECT/CT, PET/CT) in all patients with small intestine 
NENs (*evidence level 3);
 — For primary tumour detection, CT/MRI enterography, 
CT/MRI enteroclysis or endoscopic techniques may be 
required, (*evidence level 3);
 — Colonoscopy to exclude a concominant neoplastic disease 
(colon cancer) (*evidence level 4).
* evidence level according to CEBM [77]
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3.4. Pathomorphological diagnostics 
3.4.1. NENs of the small intestine
Pathogenesis
In the small intestine, well differentiated neuroen-
docrine neoplasms (NEN G1, NEN G2) are more 
frequently diagnosed than carcinomas (NECs). Most 
of the small intestinal NENs (95%) are composed of 
enterochromaffin cells (EC) responsible for serotonin 
production. Historically, they were referred to as 
‘carcinoids’. This name referred to well-differentiated 
neuroendocrine neoplasms with clinical carcinoid 
syndrome. Carcinoid syndrome is usually (95%) di-
agnosed in patients with hepatic metastases. Hormo-
nally non-active NENs are usually found by chance 
during surgery, or due to the symptoms of obstruc-
tion (35%) or gastrointestinal bleeding (14%). Acute 
abdominal symptoms appear suddenly in patients 
with dyspeptic and pain symptoms in the abdominal 
cavity (50%) which persist for years, diarrhoea, or 
weight loss (24–25%). 
In patients undergoing surgery due to a NEN of 
the small intestine, a large mesenteric tumour being 
a conglomerate of metastatic lymph nodes and a smaller 
primary tumour in the intestine are usually found in 
diagnostic imaging or during a surgical procedure. The 
lesion is rarely located in the Meckel’s diverticulum. It 
may also invade the caecum.
The risk of metastases of the small intestinal NENs 
increases with a tumour diameter of above 2 cm, mus-
cularis propria infiltration, and proliferative activity. It 
is noteworthy that tumours of the small intestine have 
a worse prognosis than neoplasms of the same size but 
located in different sites [14]. The tendency for metas-
tases to the lymph nodes and the liver significantly 
worsens the prognosis for patients with NENs of the 
small intestine. 
Diagnosis of NENs of the small intestine, due to 
a specific clinical course of the disease, is based on 
a needle biopsy assessment (of a sample obtained for 
histopathological examination) of a hepatic metastasis, 
which is often the first clinical symptom, or examination 
of the removed small intestine material and tumour 
obtained during a surgical procedure. A fine-needle 
biopsy is not recommended for the assessment of he-
patic lesions, especially as the first test, if the primary 
tumour has not been diagnosed.
Diagnostic algorithm
In the macroscopic assessment of small intestinal 
NENs, the following elements are considered:
 — The length of the intestinal section obtained for 
examination, with the description of the tumour 
location relative to the intestine resection margins, 
and the width of the removed intestinal mesentery.
 — Tumour assessment: number, size in three dimen-
sions, mutual relation of the tumours, cross-section 
appearance, considering the extravasation and foci 
of necrosis, relation of the tumour to the layers of 
the intestinal and mesenteric wall. 
 — Condition of the mucosa at the tumour site (ulcera-
tion present/not present).
 — Condition of the serosa at the tumour site.
 — Presence and size of the lymph nodes (in the case 
of a conglomerate of lymph nodes, the lesion looks 
like a mesenteric tumour).
 — Presence of other tumours in the intestinal wall.
Microscopic assessment of NENs:
Histological type of NEN according to the WHO 
classification of 2010 [13].
Histological grading (G) according to ENETS/WHO 
2010 [13, 57–59].
Pathomorphological pTNM staging according to EN-
ETS [58, 59] and AJCC/UICC [61], and clinical staging (S).
Assessment of surgical margins 
Assessment of the immunohistochemical expression 
of neuroendocrine markers: chromogranin A and syn-
aptophysin, as well as Ki67/MIB1 proliferative activity 
(obligatory).
Immunohistochemical assessment of the markers: 
NSE, CD56, CDX2, and serotonin (conditional).
Regarding 1 and 2: Histopathological type of the 
small intestinal NENs according to the WHO 2010 
classification and the histological grade of the NEN ac-
cording to the integrated ENETS/WHO 2010 system are 
presented in "Diagnostic and therapeutic guidelines for 
gastro-entero-pancreatic neuroendocrine neoplasms 
(recommended by the Polish Network of Neuroendo-
crine Tumors)" (pp. 418–443).
Regarding 3: pTNM staging classification for the 
small intestinal NENs is presented in Tables I and II.
The small intestinal NENs staging according to 
ENETS [58, 59] and AJCC/UICC [60] is presented in 
Table II.
3.4.3. Neuroendocrine neoplasms of the appendix
Pathogenesis
Most NENs of the appendix are detected during sur-
gery due to acute inflammation of the organ. Table III 
presents characteristics of the subtypes of NENs of the 
appendix.
The location of well-differentiated NENs is associated 
with the anatomical part of the organ. These tumours are 
mostly found in the end part of the appendix (75%), less 
frequently in the middle part (15%), and less frequently 
still in the proximal margin (10%). Macroscopically, they 
form hard, whitish-yellow, not encapsulated nodules, 
but their growth margin is usually expanding. Mixed 
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adenoneuroendocrine carcinomas (MANECs) tumours, 
including goblet cell carcinoid, are white, sometimes 
mucous, of 1 to 5 cm in diameter (mean diameter 2 cm), 
and show an infiltrative growth pattern. These neoplasms 
are malignant; they are classified and treated like classical 
adenocarcinomas of the appendix.
Diagnostic algorithm
Unlike NENs of the jejunum and ileum, for which a simi-
lar consensus was developed regarding the assessment 
of the T-staging, two classifications are recommended for 
NENs of the appendix: one by the European Neuroen-
docrine Tumours Society (ENETS) and the other by the 
American AJCC/UICC associations. It is recommended 
to use both classifications. First, because presently there 
is no evidence in favour of the usefulness of either of 
them. Second, in cases raising doubts as to the scope of 
therapeutic management on the basis of one classifica-
tion, the use of the other one could resolve such doubts. 
Macroscopic assessment of NENs of the appendix
A relatively low incidence of NENs of the appendix 
should always be a reason for very careful macroscopic 
examination and careful sample collection, following 
the standard. The samples should be collected from 
the end of the appendix, its middle part and base (the 
proximal colonic margin), and the size of the tumour 
should be stated. 
The macroscopic description should include  
the following:
The length of the appendix obtained for examination, 
with the description of the tumour location relative to 
the resection margin.
Table I. TNM UICC/AJCC and ENETS classification systems [60]
Tabela I. Klasyfikacja TNM UICC/AJCC i ENETS [60]
Feature T — primary tumour x Comment
TX The primary tumour cannot be assessed.
T0 No evidence of primary tumour
T1 Tumour invades lamina propria or submucosa and ≤ 1 cm
T2 Tumour invades muscularis propria and/or > 1 cm
T3 Tumour penetrates muscularis propria and invades subserosal tissue
T4 Tumour invades serosa or adjacent structures
N — regional lymph nodes Comment
NX Lymph nodes cannot be assessed.
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M — distant metastasis xx Comment
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
x — If more than one tumour is present, we add ‘m’ to the letter T, regardless of the size; xx — If there is evidence of distant metastasis, the anatomical site should be 
specified in the brackets as follows: PUL for pulmonary; HEP for hepatic; and OSS for osseous.
Table II. Small intestinal GEP NENs staging
Tabela II. Stopień klinicznego zaawansowania (staging) GEP NEN jelita cienkiego
Stage T feature N feature M feature
I T1 N0 M0
IIA T2 N0 M0
IIB T3 N0 M0
IIIA T4 N0 M0
IIIB Tumour of any diameter N1 M0
IV Tumour of any diameter any M1
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Tumour assessment: the size in three dimensions, and 
cross-section appearance.
Condition of the serosa and mesoappendix at the tu-
mour site — it is necessary to collect numerous samples.
Microscopic assessment of NENs of the appendix:
1. Histological type of NEN according to the 2010 WHO 
classification [57].
2. The histological grade (G) according to ENETS [13, 57–59].
3. Pathomorphological pTNM staging according to 
ENETS [58, 59] and AJCC/UICC [60].
4. Assessment of immunohistochemical expression of neu-
roendocrine markers: chromogranin A and synaptophy-
sin, as well as Ki67/MIB1 proliferative activity is obligatory. 
Immunohistochemical assessment of NSE, CD56, CDX2 
markers and serotonin is recommended conditionally, 
in the case of metastatic differentiation, especially if the 
original site of the neoplasm is unknown. A positive reac-
tion with cdx-2 and/or serotonin indicates an intestinal, 
particularly ileocaecal, origin of the neoplasm. 
Regarding 1 and 2: Histological types of NENs ac-
cording to the World Health Organisation (WHO) and 
the criteria for tumour staging are presented above for 
NENs of the small intestine.
Regarding 3: The ENETS and AJCC/UICC histo-
pathological grading of NENs, regarding the T-feature 
Table III. Characteristics of the morphological subtypes of NENs of the appendix
Tabela III. Charakterystyka podtypów morfologicznych NEN wyrostka robaczkowego
Type Subtype and characteristics
Neuroendocrine neoplasms
NEN
Enterochromaffin cell (EC cell NEN)
Most cases of NENs of the appendix
They form characteristic solid nests, islets surrounded by a circumferential palisade of cells
The cells are monomorphic, without any features of polymorphism, without mitotic activity, and with Ki67 index 
below 2%; they are high-grade G1
They invade in a dispersed manner the muscularis propria of the appendix wall and nervous trunks; they are 
angioinvasive
In 10–40% of cases, they invade the subserosa fat tissue
Regardless of their aggressive growth, and unlike NENs of the caecum, they rarely cause lymph node metastases or 
distant metastases
It produces serotonin, substance P, S100+
They show positive reactions with chromogranin A, synaptophysin, keratin 8 and 19, CD56, cdx2 and usually 
negative reactions with keratin 7 and 20, CEA and TTF1
L cell NENs
Tumours occur rarely
They produce glucagon-like peptides, PP/PYYY
They create a characteristic growth type in the form of trabecular structures
Mostly 2–3 mm in diameter
Tubular carcinoid
Occurs in young patients (around 29 years of age)
This NEN subtype is sometimes misdiagnosed as adenocarcinoma. It creates small tubes with mucus, short 
trabecular structures, but no solid nests of neoplastic cells are evident
It develops at the crypt base
It produces glucagon, serotonin, s100 minus
Mixed adenoneuroendocrine 
carcinoma (MANEC)
Goblet cell carcinoid
It usually affects older patients (mean age 52 years)
Invasion of the submucosa is predominant
Positive reaction to mucus is observed
It produces serotonin, somatostatin and carcinoembryonic antigen (CEA)
It is reported like adenocarcinoma of the appendix
Neuroendocrine carcinoma 
(NEC)
Small-cell NEC
It occurs very rarely
It is usually a component of the neoplasm beside adenocarcinoma
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of NENs of the appendix are presented in Table IV, and 
the clinical staging is demonstrated in Table V.
Prognostic factors for NENs of the appendix
Acording to European and American guidelines, 
tumour size and infiltration of the mesoappendix are 
important risk factors of NENs of the appendix; they 
are the criteria for division into pTNM classification 
stages. According to a report by the College of Ameri-
can Pathologists, cases in which the diameter of the 
tumour is above 1 cm and below 2 cm and infiltration 
of the mesoappendix is present should be treated as 
ones with uncertain prognosis. Potentially benign 
tumours are smaller than 1 cm and do not invade the 
mesoappendix. It is worth emphasising that according 
to the pTNM 2010 classification, neuroendocrine car-
cinomas (NECs) of the appendix and MANEC mixed 
neoplasms composed of classical and neuroendocrine 
carcinoma components, as well as goblet-cell carci-
noids, are diagnosed following the criteria for classical 
carcinomas, and not those for NENs. 
Apart from the above features, the histopathological 
report should include the assessment of margins: proxi-
mal, distal, mesoappendiceal and radial, as well as the 
angioinvasion of blood vessels. It should be noted that 
it is necessary to examine the colonic proximal margin, 
near the base of the appendix. Invasion of the caecum/ 
/colon determines the treatment method. During the 
assessment of the slides, particular attention should 
also be paid to small periserosal vessels, which could 
be ignored, especially if the samples from the periphery 
of the tumour were inadequately collected. 
Minimal consensus statement on pathomorphological 
examination:
 — Minimal histopathological report for NENs of the small 
intestine and the appendix should include:
• histological type of the neoplasm according to WHO 
classification, considering the division into well-
differentiated neuroendocrine neoplasms (NENs) 
and neuroendocrine carcinomas (NECs) or mixed 
neoplasms (MANECs);
• histological grading (G) referring to well-differenti-
ated neoplasms (NEN G1, NEN G2);
• pTNM histopathological staging according to ENETS 
and AJCC/UICC classifications (it is important to 
provide affiliation of the classification in each case);
• assessment of surgical margins.
 — The histopathological diagnosis of NEN must be confirmed 
by immunohistochemical tests assessing expression of 
Table IV. pTNM of NENs of the appendix according to the ENETS and AJCC/UICC classifications
Tabela IV. pTNM NEN wyrostka robaczkowego według klasyfikacji ENETS i AJCC/UICC
T feature pTNM according to ENETS pTNM according to AJCC/UICC
T1 ≤ 1 cm invading submucosa and muscularis propria 1A — tumour ≤ 1 cm in the biggest dimension
1B — tumour > 1 cm and ≤ 2 cm
T2 Tumour ≤ 2 cm and/or minimally (up to 3 mm) invading 
mesoappendix
Tumour > 2 cm and ≤ 4 cm or tumour invading the caecum
T3 Tumour > 2 cm and/or invading subserosa/mesoappendix to a 
depth greater than 3 mm
Tumour > 4 cm or invading the ileum
T4 Tumour invades serosa or adjacent organs Tumour invades the peritoneum or other organs or tissues, e.g. 
abdominal wall or skeletal muscles
Table V. Staging of NENs of the appendix according to ENETS [58, 59]
Tabela V. Stopień klinicznego zaawansowania (staging) NEN wyrostka robaczkowego wg. ENETS [58, 59]
Stage T feature N feature M feature
I T1 N0 M0
IIA T2 N0 M0
IIB T3 N0 M0
IIIA T4 N0 M0
IIIB Tumour of any diameter N1 M0
IV Tumour of any diameter any N M1
* evidence level according to CEBM [77]
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the neuroendocrine markers: synaptophysine and chro-
mogranin A, as well as Ki67 proliferative activity using 
the MIB1 antigen (*evidence level 3).
4. Treatment
4.1. Surgical treatment 
NENs of the midgut are usually located in the distal 
part of the small intestine or in the appendix. They fre-
quently present in multi-focal form. The preferred treat-
ment of intestinal NENs is partial or multiple resection 
(a radical treatment) or palliative, cytoreductive surgery 
reducing the tumour mass by approximately 90%. 
The Polish recommendations concerning the treat-
ment of NENs of the appendix are as follows:
for tumours of 1 cm and less in diameter, located 
in the distal part of the appendix, without negative 
prognostic factors, simple appendectomy should be 
applied [61–63];
indications for right-sided hemicolectomy are the 
following tumour features:
 — diameter of more than 1 cm,
 — tumour location at the base of the appendix,
 — tumour of any size invading the mesoappendix,
 — tumour present in the resection margin,
 — mixed exo- and endocrine tumour,
 — G2 feature (confirmed by two pathomorphologists),
 — goblet cell carcinoid,
 — inability to assess the completeness of tumour 
resection, or doubts as to the completeness of the 
neoplasm resection.
In NECs the management is the same as in carcino-
mas. In the case of NENs of the appendix with hepatic 
metastasis, the recommended management is right-sided 
hemicolectomy including removal of the metastasis 
(anatomical and non-anatomical resections). In the case 
of multiple metastases, a palliative surgery removing the 
metastases should be considered (resection, thermoabla-
tion, chemoembolisation) [64, 65]. In selected patients, liver 
transplantation may be considered; the decision should 
follow a careful radioisotope diagnostics, excluding the 
presence of other, remote neoplastic foci [4].
Minimal consensus statement on surgical treatment:
Surgical treatment of the midgut tumours involves 
a complete removal of the tumour within the healthy tissue 
(*evidence level 3).
4.2. Pharmacological treatment
Pharmacotherapy of small intestine NENs consists of 
biotherapy and chemotherapy. The leading biotherapy 
method is treatment with SSA (lanreotide and octreo-
tide), which are indicated for the symptomatic therapy 
of hormonally active NENs of the small intestine. SSA 
are the preferred treatment option for carcinoid crisis 
[18, 25]. There are ongoing clinical studies on the use 
of new SSA (pasireotide) in cases of resistance to the 
standard treatment of carcinoid syndrome [66]. 
Interferon alpha may be administered for the same 
indications as SSA, except for carcinoid crisis. The ef-
fectiveness of the treatment is similar to that of SSA, 
and the response to treatment is slightly delayed. 
Combined therapy with interferon and SSA analogue 
is not recommended [2, 4, 67]. There is no previous 
experience of the use of INF-α for GEP NENs manage-
ment in Poland. Preliminary data suggests the efficacy 
of combined everolimus plus octreotide LAR regimen in 
the treatment of advanced neuroendocrine neoplasms 
with the symptoms of carcinoid syndrome (RADI-
ANT-2) [68]. Everolimus therapy can be considered in 
patients with generalised NENs of the small intestine 
in progression after unsuccessful treatment with SSA, 
and failure or inability to use other treatment options 
(including PRRT — see below). 
Due to limited effectiveness, chemotherapy is not 
recommended as a treatment in patients with well-
differentiated, metastatic neuroendocrine neoplasms 
of the small intestine [2, 4, 17, 69].
Heart failure resulting from expansion of the disease 
to the cardiac cavities is associated with shortened life 
expectancy in patients, and it requires proper cardio-
logical and/or cardiosurgical treatment [21, 31].
4.2.1 Treatment with SSA in patients with NENs of 
the small intestine
Symptomatic treatment in carcinoid syndrome
 — In long-term therapy, we use octreotide LAR (10– 
–30 mg i.m. every four weeks, but the lowest dose 
is rarely used), lanreotide Autogel (60–120 mg s.c. 
every 4–8 weeks, but the lowest dose is rarely 
used).
 — If carcinoid syndrome symptoms recur before the 
next SSA analogue injection is due, the interval 
between injections may be reduced to three weeks.
 — During the treatment, a significant reduction in the 
frequency of carcinoid syndrome symptoms (diar-
rhoea in 60–70% of patients, flushing in 70–80% of 
patients) and lower levels of biochemical markers 
(5-HIAA in 40–60% of patients) are observed.
 — Long-term treatment with SSA significantly im-
proves the quality of life in patients with carcinoid 
syndrome.
* evidence level according to CEBM [77]
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Carcinoid crisis treatment
 — There are no clear EBM recommendations for the 
management of carcinoid crisis.
 — The soonest possible introduction of somatostatin 
analogue therapy is of the greatest importance; 
a short-acting SSA in high doses is usually admin-
istered intravenously (octreotide: 25–500 µg/h i.v.; 
on average 100–200 µg/h i.v.) [70].
 — In carcinoid crisis (particularly in NENs of the 
foregut), the administration of glucocorticoids and 
antihistamines can be considered. 
 — It is necessary to introduce intensive symptomatic 
treatment of dehydration, acute renal failure, hy-
percalcaemia, arterial hypertension or hypotonia, 
cardiac failure and infection [27].
Preparation of patients with NENs of the small 
intestine and the appendix for surgery
 — There are no clear recommendations for preparation 
of patients with NENs of the small intestine and the 
appendix for surgery [71].
 — In patients with carcinoid syndrome, pre-operative 
administration of short-acting SSA should be consid-
ered, regardless of the long-acting SSA therapy (e.g. 
octreotide 200–300 µg s.c. before the surgery and/or 
continuous infusion of 50–100 µg/h intraoperatively 
and/or 24–48 h after the surgery).
 — In patients with hormonally non-active NENs, it 
is recommended that a short-acting SSA should be 
available during the operation, and administered in 
the case of an unstable haemodynamic condition.
Stabilisation of neoplastic disease in patients 
with well-differentiated NENs of the small intes-
tine in the generalisation period (see "Diagnostic 
and therapeutic guidelines for gastro-entero-pan-
creatic neuroendocrine neoplasms (recommended 
by the Polish Network of Neuroendocrine Tu-
mors)" [pp. 418–443])
 — Based on the PROMID study, octreotide LAR (30 mg 
i.m. every four weeks) was registered for the treat-
ment of patients with advanced NENs originating 
from the midgut or of unknown primary sites.
 — Phase III clinical trials (CLARINET) indicate that 
lanreotide Autogel (120 mg every four weeks) has 
antiproliferative effects on midgut NENs.
Other comments on treatment with SSA:
 — It is recommended to discontinue SSA before the 
planned receptor examinations SPECT or PET-CT: at 
least four weeks in the case of long-acting prepara-
tions, and 24–48 hours for short-acting ones.
 — Treatment with SSA should be terminated before the 
planned administration of PRRT; a six-week interval 
is recommended for long-acting formulations, and 
a 24-hour interval for short-acting ones [3]. 
Symptomatic treatment:
In patients with secretory diarrhoea due to NENs of 
the small intestine, loperamide, ondasetron and cholesty-
ramine are used to bind bile acids, as well as pancreatic 
enzymes and B vitamins, in cases of deficiency [16].
4.3. Isotope therapy 
Chemotherapy is not effective in advanced, inoperable 
NENs of the small intestine; therefore, in each case ra-
dioisotope therapy should be considered. Qualification 
for the treatment is conducted according to the rules 
described in the general section. A partial remission of 
the disease can be achieved in approximately 18–22% of 
the patients with midgut neoplasms [72, 73]. In patients 
with small intestine NENs and symptomatic carcinoid 
syndrome, there is a risk for aggravation of carcinoid syn-
drome symptoms or even carcinoid crisis. In these cases, 
a proper preparation of the patient is essential, including 
intensive paraenteric hydration and administration of 
short-acting somatostatin analogues [74]. In patients with 
negative receptor scintigraphy and evidence of mIBG 
accumulation in the tumour or metastases, therapy with 
131I-mIBG can be considered [75] (*evidence level 3).
Minimal consensus statement on the treatment of 
NENs of the small intestine and the appendix:
 — the preferred treatment of intestinal NENs is partial or 
multiple resection and removal of potential metastases 
(radical treatment) or palliative, cytoreductive surgery 
(*evidence level 3);
 — SSA are the preferred treatment in the case of hormonally 
active NENs of the small intestine (carcinoid syndrome 
and carcinoid crisis), and in patients with hormonally 
non-active NENs they can be used as antiproliferative 
therapy (*evidence level 1);
 — for advanced, inoperable NENs of the small intestine, 
radioisotope therapy should be considered (*evidence 
level 2);
 — everolimus therapy can be considered in patients with 
generalised NENs of the small intestine in progression 
after unsuccessful treatment with SSA and failure or in-
ability to use other treatment options (*evidence level 4).
Proposed treatment sequence:
 — surgical treatment,
 — SSA in hormonally active and non-active NENs,
 — radioisotope therapy,
* evidence level according to CEBM [77]
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 — targeted therapies (everolimus),
 — symptomatic treatment.
4.4. Monitoring of the treatment
Determination of CgA and 5-HIAA may be useful for 
the assessment of treatment efficacy in patients with 
small intestine NENs. In patients with carcinoid syn-
drome treated with SSA, lower excretion of 5-HIAA and 
decreased levels of chromogranin A are associated with 
reduced intensity and frequency of clinical symptoms 
(flushing, diarrhoea). 
However, it is believed that 5-HIAA excretion does 
not reflect the progression or the response to treatment 
as precisely as the monitoring of CgA concentration. 
A high association (80%) between changes in the tumour 
size and concentration of chromogranin A has been 
observed. An even higher association (88%) was found 
in a group of patients with non-secreting tumours, in 
whom other markers could not be used [29]. However, 
in certain patients a very good clinical response to the 
treatment of carcinoid syndrome with SSA has been 
observed, without lowered CgA levels [76].
The clinical course, imaging of the size of lesions, and 
monitoring of chromogranin A levels can be useful to as-
sess the applied treatment of small intestinal NENs. The 
frequency of follow-up examinations depends on NEN 
differentiation and staging, as well as on the introduced 
treatment (see "Diagnostic and therapeutic guidelines 
for gastro-entero-pancreatic neuroendocrine neoplasms 
(recommended by the Polish Network of Neuroendocrine 
Tumors)" [pp. 418–443]). The anamnesis and physical 
examination should be performed every three months, 
and imaging examinations (three-phase CT scanning of 
the abdominal cavity) and biochemical indicators (CgA 
and 5-HIAA) should be controlled.
After radical surgery with a curative intent:
 — in patients with NEN G1 and G2 every 6-12 months,
 — in patients with NEC every three months. 
 — Not curatively treated:
 —  in patients with NEN G1 every six months,
 — in patients with NEN G2 every three months,
 — in patients with NEC every three months. 
Minimal examination includes: CgA, 5-HIAA and 
triphasic CT.
In patients with carcinoid heart disease, echocar-
diographic examination and NT-proBNP should be 
repeated every 6–12 months. If the disease progresses, 
follow-up imaging and biochemical tests need to be 
conducted more frequently, every three months.
Minimal consensus statement on follow-up:
 — follow-up visits should be planned individually for each pa-
tient, considering the clinical picture, grading and staging of 
the disease, and its treatment. In general, patients should be 
followed every 6–12 months for NEN G1, every 3–12 months 
for NEN G2 and every three months for NEC;
 — minimal examination includes: CgA, 5-HIAA and 
triphasic CT;
 — in patients with carcinoid heart disease, echocardiographic 
examination and NT-proBNP every 6–12 months.
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